Scientists Strike Back at the Viral Phantom Infecting 95% of Humanity

Researchers have identified a powerful new antibody that targets a critical weakness in the Epstein-Barr virus (EBV), a pathogen residing in the vast majority of the global population. While often dormant, EBV is linked to serious conditions including various cancers and multiple sclerosis. This newly developed antibody, known as mAb 155, effectively blocks the virus from entering host cells by neutralizing a specific protein complex, potentially paving the way for the first successful vaccines and therapeutic treatments against this pervasive infection.